Table 5. The interactions between copy number variations and TNM stage on the prognosis of lung adenocarcinoma.

	Overall survivala (N = 313)		Progression free survival b(N = 313)
	Crude HR(95%CI)	Adjusted HR(95%CI)	Crude HR(95%CI)	Adjusted HR(95%CI)
PBXIP1 and TERT
both amplification	1.00	1.00	1.00	1.00
either amplification	0.53(0.35–0.81)	0.54(0.35–0.84)c	0.72(0.50–1.03)	0.76(0.52–1.10)c
both nonamplification	0.52(0.29–0.94)	0.51(0.28–0.93)c	0.52(0.31–0.89)	0.55(0.32–0.94)c
Stage and PBXIP1
stage 3–4 and amplification	1.00	1.00	1.00	1.00
stage 3–4 and nonamplification	0.64(0.41–1.00)	0.59(0.37–0.93)d	0.89(0.60–1.31)	0.85(0.57–1.27)d
stage 1–2 and amplification	0.28(0.14–0.55)	0.26(0.13–0.53)d	0.37(0.21–0.66)	0.36(0.20–0.66)d
stage 1–2 and nonamplification	0.18(0.10–0.33)	0.15(0.08–0.28)d	0.29(0.18–0.47)	0.27(0.17–0.44)d
Stage and TERT
stage 3–4 and amplification	1.00	1.00	1.00	1.00
stage 3–4 and nonamplification	0.53(0.28–0.98)	0.50(0.27–0.94)d	0.48(0.28–0.84)	0.46(0.26–0.80)d
stage 1–2 and amplification	0.19(0.11–0.33)	0.18(0.10–0.32)d	0.28(0.19–0.43)	0.28(0.19–0.42)d
stage 1–2 and nonamplification	0.38(0.21–0.68)	0.35(0.19–0.62)d	0.32(0.19–0.53)	0.30(0.18–0.52)d

^aOverall survival was calculated by subtracting the date when the patient was first treated from the date of death, and patients were censored when lost of follow-up.

^bProgression free survival was calculated by subtracting the date of first treatment from the date of recurrence of, metastasis of or death from lung adenocarcinoma.

^cAdjustment: age, gender, smoking status and TNM stage.

^dAdjustment: age, gender and smoking status.